NOVARTIS AG-ADR PATROCINADO

NVS is the ticker symbol for Novartis AG, a Swiss multinational pharmaceutical company. The stock represents ownership in a company that develops and markets prescription medicines and innovative therapies. NVS trades as an American Depositary Receipt (ADR) on the New York Stock Exchange, giving U.S. investors access to shares of the underlying Swiss-listed company.

Recent performance for NVS depends on current market conditions and news specific to the pharmaceutical sector. For the latest price changes, daily moves, and short-term trends, refer to the live NVS quote and performance chart on this page, which reflect the most up-to-date market data available.

Evaluating NVS involves comparing metrics such as the price-to-earnings ratio, price-to-sales, and dividend yield against peers in the pharmaceutical industry. Analysts also consider pipeline strength, patent expirations, and growth prospects. Because valuation depends on current prices and earnings estimates, check the latest NVS financial data and ratios shown on this page for accurate figures.

NVS can be purchased through a brokerage account that offers U.S.-listed stocks and ADRs. Investors typically place a buy order specifying the number of shares and order type, such as market or limit. Fractional shares may be available depending on the broker. Verify trading eligibility and any ADR-related fees before placing an order.

Novartis has historically paid dividends, and NVS ADR holders generally receive distributions after applicable foreign taxes and fees. Dividend amounts and payment schedules can vary based on the company's earnings and board decisions. For the current dividend rate, yield, and recent payment dates, consult the dividend information displayed on this page.

Key risks include drug development failures, patent expirations, regulatory approvals, pricing pressure, and competition from generic and branded rivals. Currency fluctuations between the Swiss franc and U.S. dollar can also affect ADR returns. Additionally, legal or compliance issues and broader healthcare policy changes may impact results. Review NVS risk disclosures and recent filings for a fuller picture.